Design Therapeutics (DSGN)

• Market cap: $652M
• 1 day: -2.79%
• 5 days: -5.69%
• 1 month: -33.88%
• 3 months: 2.05%
• 6 months: 16.65%
• Year to date: 14.73%
• 1 year: 160.35%
• 5 years: -60.03%
• 10 years: -74.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Employees: 54